Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

janssen_latest_logo_on_sign

Janssen’s Erleada meets primary endpoints in ongoing trial into metastatic castration-sensitive prostate cancer

January 31, 2019
Research and Development Cancer, Erleada, Janssen, pharma, prostate cancer

Janssen has revealed that its androgen receptor (AR) inhibitor Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), has been …

News
pharmafocus_janfeb_2019_cover

Read Pharmafocus January/February 2019 edition online now!

January 30, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Cancer, Counterfeit drugs, NHS, Pharmafocus, WHO, brexit, pharma, vaccines

We’re slowly edging towards warmer months, but the New Year brings more than just the promise of more amicable weather; …

News
cancer-cells-541954_960_720

Israeli biotech claims it has developed cure for cancer

January 30, 2019
Research and Development Cancer, MuTaTo, biotech, israel, lung cancer, oncology

An Israeli biotech has claimed that it has developed a complete cure for cancer. Speaking to the Jerusalem Post, Dan …

News

Imbruvica combo scores expanded FDA approval in most common adult form of leukaemia

January 29, 2019
Manufacturing and Production, Sales and Marketing AbbVie, Cancer, Janssen, imbruvica, leukaemia, pharma

It’s big news for Janssen and AbbVie as it emerged that their jointly-developed Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) …

News
800px-t_lymphocyte_16760076824

Precision cancer treatment for dogs moves towards human testing

January 29, 2019
Manufacturing and Production CAR-T therapy, Cancer, Precision Medicine, car t therapy, dogs, t cells, t-cells

Scientists at the University of Missouri have developed a patient specific, precision medicine treatment for bone cancer in dogs. The …

News

People in England will be able to pay the NHS to sequence their genetic data, if they share it with scientists

January 28, 2019
Sales and Marketing Alzheimer's, Cancer, England, NHS, genetic data, genomes, health

The NHS will provide paid-for health reports, informing patients as to the likelihood that they will develop diseases such as …

News

Diagnosis at stages 1-3 increases cancer survival rate significantly

January 25, 2019
Medical Communications Cancer, England, NHS, health, oncology

Adults diagnosed with stage 1 skin, prostate or breast cancer have the same chance of still being alive the following …

News

EMA rejects Lilly’s Lartruvo in soft tissue cancer following trial failure

January 24, 2019
Sales and Marketing Cancer, EMA, Eli Lilly, Lartruvo, pharma

Eli Lilly has been dealt a blow as the European Medicines Agency announced its recommendation for soft tissue cancer patients …

News
gsk_rd_harlow

GSK acquires oncology firm Tesaro for $5.1 billion

January 23, 2019
Research and Development Cancer, GSK, Tesaro, oncology, ovarian cancer

British multinational GlaxoSmithKline (GSK) have acquired US oncology firm Tesaro for $5.1 billion (£4 billion). Tesaro, a Massachusetts-based clinical stage …

News
amgen_hq

Amgen’s Blincyto secures expanded indication in Europe for acute lymphoblastic leukaemia

January 23, 2019
Research and Development, Sales and Marketing Ammgen, Cancer, Europe, European Commission, blincyto, leukaemia, pharma

The European Commission has chosen to expand the authorised indication for Amgen’s Blincyto (blinatumomab) in the region, it has emerged, …

News
mesothelioma

Pushing for progress in mesothelioma

January 21, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, mesothelioma, pharma

Mesothelioma.net reviews the wide array of latest advances in treatment and care for patients affected by the challenging cancer as …

Feature
lilly_building_with_american_flag_web

Lilly’s Lartruvo/chemo combo surprises with Phase 3 failure in soft tissue carcinoma

January 21, 2019
Research and Development, Sales and Marketing Cancer, Eli Lilly, carcinoma, chemotherapy, pharma, trial failure

Eli Lilly has reluctantly pulled back the curtain on new Phase 3 data for its platelet-derived growth factor receptor alpha …

News
imp_pologne2

NICE recommends Pierre Fabre’s Braftovi in BRAF V600-mutated advanced melanoma

January 21, 2019
Sales and Marketing Braftovi, Cancer, NICE, Pierre Fabre, UK, melanoma, pharma

Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by …

News
novartis_window

Canada Health approves Novartis’ CAR-T therapy Kymriah

January 18, 2019
Medical Communications CAR T, CAR-T, Canada, Cancer, Kymriah, Novartis, oncology

Health Canada has approved Novartis’ CAR-T therapy Kymriah for use in paediatric and young adult patients aged between three and …

News

Eli Lilly’s Verzenios scores NICE recommendation for advanced breast cancer

January 17, 2019
Sales and Marketing Cancer, Eli Lilly, NICE, Verzenios, breast cancer, pharma

Breast cancer patients in England and Wales now have access to another treatment option, as NICE announces its recommendation of …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026